Shu-Hai Zhao

This inventor holds 25 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Antiviral Compounds. Top assignees: Roche Palo Alto LLC, Syntex (u.s.a.) Inc., Hoffmann-La Roche Inc.. Active years: 1999-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shu-Hai Zhao. Retrieved from https://idiyas.com/inventor/shu-hai-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 2)

% Patents Active = 16.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 135(Granted Patents)

Location History:

Sunnydale, CA (US) (1999)
Sunnyvale, CA (US) (1999 - 2013)
Cupertino, CA (US) (2009 - 2016)

Company Filing History:

Hoffmann-La Roche Inc.

patents

Years Active: 1999-2016

Loading Chart...

Areas of Expertise:

Antiviral Compounds

Indazoles

Benzoxazine Derivatives

Dihydropyridone Amides

5-HT6 Antagonists

Quinazolinone Derivatives

Benzothiazines

Aminoalkoxyindoles

Aryl Pyrimidine Derivatives

Chromans

Benzodioxanes

Carboxamide Derivatives

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9403805 - Antiviral compounds (2016-08-02),

2. 9206191 - Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection (2015-12-08),

3. 9090559 - Antiviral compounds (2015-07-28),

4. 8377931 - Benzoxazine derivatives and uses thereof (2013-02-19),

5. 8372865 - [object Object] (2013-02-12),

6. 8288552 - [object Object] (2012-10-16),

7. 8163929 - [object Object] (2012-04-24),

8. 8153808 - Dihydropyridone amides as P2X7 modulators (2012-04-10),

9. 7759389 - Chroman derivatives and uses thereof (2010-07-20),

10. 7754759 - [object Object] (2010-07-13),

11. 7741326 - Indole and benzofuran 2-carboxamide derivatives and uses thereof (2010-06-22),

12. 7528250 - Chroman derivatives and uses thereof (2009-05-05),

13. 7378415 - Benzoxazine and quinoxaline derivatives and uses thereof (2008-05-27),

14. 7368567 - Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists (2008-05-06),

15. 7365063 - Quinazolinone and benzoxazinone derivatives and uses thereof (2008-04-29),

Title: Innovations by Shu-Hai Zhao: Pioneering Antiviral Compounds

Introduction

Shu-Hai Zhao, based in Cupertino, California, stands out in the field of medicinal chemistry with an impressive portfolio of 25 patents. His work primarily focuses on antiviral compounds and their applications in treating critical viral infections. Zhao's groundbreaking innovations exemplify the intersection of science and technology, particularly in pharmaceuticals.

Latest Patents

Among his latest patents, the invention of antiviral compounds for the treatment of hepatitis C virus (HCV) infection is particularly noteworthy. This invention encompasses compounds, compositions, and methods that significantly contribute to the therapeutic landscape for HCV. In addition, Zhao has developed novel indazole compounds aimed at the treatment and prophylaxis of respiratory syncytial virus infection. The compounds described in this patent reveal unique structures with defined properties, paving the way for new treatment options.

Career Highlights

Zhao's career includes valuable contributions to major pharmaceutical companies, such as Roche Palo Alto LLC and Syntex (U.S.A.) Inc. His experience in these organizations has allowed him to refine his expertise in drug development and research, leading to significant advancements in antiviral therapies.

Collaborations

Throughout his career, Shu-Hai Zhao has collaborated with notable professionals in the field, including Jacob Berger and Robin D. Clark. These partnerships have fostered an environment of creativity and innovation, resulting in impactful research and development outcomes.

Conclusion

Shu-Hai Zhao's extensive experience and innovative approach to drug discovery continue to influence the field of antiviral research. With his impressive patent portfolio and collaborative efforts, he remains a key figure in the ongoing battle against viral infections, contributing to the enhancement of public health through science and innovation.

Profile summary based on public USPTO records.